Inquiry Basket
Loading ......
Beta-2 microglobulin is a small, highly conserved protein that forms the invariant light chain of the major histocompatibility complex class I molecule. It sits on the surface of nearly all nucleated cells, where together with a polymorphic heavy chain and a peptide it builds the platform that displays intracellular antigens to CD8+ T cells. Beyond this structural role, free beta-2 microglobulin circulates in serum and appears in urine, and its levels are interpreted as signals of immune activation, renal handling, and tumor burden. The protein has also become central to two very different research frontiers, the loss of its expression as a mechanism of immune evasion in cancer, and its aggregation into amyloid fibrils in patients on long-term dialysis.
Beta-2 microglobulin is a 99-residue, approximately 11.8 kDa polypeptide that adopts a classic immunoglobulin-like beta-sandwich fold. Seven antiparallel beta strands arrange into two opposing sheets that are packed against one another, an architecture shared with the membrane-proximal alpha3 domain of the class I heavy chain. A single disulfide bond, formed between conserved cysteine residues near the amino and carboxy termini, stabilizes the fold. The protein is not glycosylated and lacks a transmembrane segment, so it remains noncovalently tethered to the heavy chain at the cell surface and is released into body fluids as cells turn over. The compact size and simple topology of beta-2 microglobulin make it one of the most abundant and most readily measured soluble proteins of immune origin. Its structure is nearly identical across individuals, in contrast to the highly polymorphic heavy chain it partners with, which is why beta-2 microglobulin serves as the constant scaffolding that allows a single structural principle to present an enormous diversity of peptides.
Newly synthesized heavy chains first associate with calnexin and then bind beta-2 microglobulin in the endoplasmic reticulum, forming a heterodimer that is unstable until a peptide is loaded. The heterodimer is recruited into the peptide-loading complex, a multiprotein assembly that includes calreticulin, the oxidoreductase ERp57, tapasin, and the transporter associated with antigen processing that delivers cytosolic peptides into the lumen. ER aminopeptidases trim peptides to the optimal length before they settle into the binding groove. Beta-2 microglobulin is essential for this pathway because the heavy chain alone is poorly folded and rapidly degraded, and only when beta-2 microglobulin is present does the complex gain the stability needed to sample peptides and then exit the endoplasmic reticulum. Once a high-affinity peptide is bound, the trimeric complex dissociates from the loading machinery and moves through the Golgi to the plasma membrane. The dependence of surface expression on beta-2 microglobulin explains why cells lacking the protein fail to display class I at all, a property that has made beta-2 microglobulin a useful genetic tool for studying antigen presentation.
Figure 1. Model of the peptide-loading complex. (Source: Schölz C, et al. 2005)
At the cell surface, the beta-2 microglobulin stabilized complex presents peptides that are sampled from the intracellular proteome, including fragments of viral proteins and cancer-specific antigens. CD8+ T cells scan these peptides through their T cell receptors, and a mismatch between the displayed peptide and the host repertoire triggers cytotoxic responses that eliminate infected or transformed cells. Beta-2 microglobulin therefore underpins the constant surveillance that keeps most intracellular threats in check. The invariant nature of the light chain means that its contribution is qualitative rather than peptide specific, but without it the groove cannot form or be transported. This arrangement also creates a vulnerability, because any event that reduces beta-2 microglobulin expression strips the cell of its identifying markers and removes the signal that normally licenses cytotoxic T cells to ignore healthy tissue. The balance between stable presentation and rapid turnover is thus a central feature of immune homeostasis, and the half life of the empty complex is short unless peptide occupies the groove.
Because beta-2 microglobulin is shed during normal cell turnover and membrane recycling, a low baseline concentration is present in serum, where it reflects the rate of class I turnover across nucleated cells. The kidney filters the free protein readily at the glomerulus, but almost all of the filtered load is reabsorbed and degraded by proximal tubule cells, so only a trace appears in urine under healthy conditions. When glomerular filtration falls, serum beta-2 microglobulin rises, and when proximal tubule function is impaired, urinary beta-2 microglobulin climbs instead. Measuring both compartments therefore helps distinguish a decline in filtration from a defect in tubular reabsorption. Free beta-2 microglobulin also behaves as an acute-phase associated marker, rising with immune activation and with certain hematologic malignancies where tumor burden correlates with circulating levels. Its small size and freedom from glycosylation make it straightforward to quantify with antibody-based assays, and its concentrations in cerebrospinal fluid and other compartments are used in research to probe local immune or barrier status.
Figure 2. Cartoon depicting our hypothesis on urinary biomarker filtration, reabsorption and secretion. (Source: de Rooij ENM, et al. 2024)
Natural killer cells monitor class I expression through inhibitory receptors that recognize self major histocompatibility complex molecules, a process called licensing or education. In mice lacking beta-2 microglobulin, surface class I is absent, yet these animals are not destroyed by autoimmunity, because natural killer cells that develop without engaging self class I become hyporesponsive rather than primed to kill. Acute loss of class I in an otherwise normal host produces a more nuanced outcome, because widespread down-regulation induces tolerance, whereas loss on a small subset of hematopoietic cells can provoke killing, and inflammation can convert tolerance into missing-self reactivity. These findings show that the absence of beta-2 microglobulin does not uniformly signal danger. Instead, the immune system interprets missing class I in the context of developmental history and inflammatory cues. This nuance matters clinically, because tumors that silence beta-2 microglobulin to escape T cells may still become visible to natural killer cells through the same missing-self logic, a trade-off that shapes therapeutic responses.
Loss of beta-2 microglobulin is one of the best-documented routes by which tumors evade immune detection. Mutations, copy-number loss, or epigenetic silencing of the B2M gene prevent class I assembly, so neoantigens are no longer presented and CD8+ T cells lose their target. This mechanism has been linked to acquired resistance to checkpoint inhibitors, where tumors that initially responded later lose beta-2 microglobulin and relapse. The same defect can undermine engineered T cell therapies that depend on class I presentation. Importantly, the absence of beta-2 microglobulin is not an absolute dead end for immunotherapy, because the missing-self state can engage natural killer cells and because CD4+ T cells can still recognize class II presented antigens or stromal cues. Research now focuses on detecting B2M alterations before treatment, combining agents that recruit natural killer cells, and restoring antigen presentation where feasible. Beta-2 microglobulin thus sits at the center of a recurring puzzle in immuno-oncology, how to keep tumor antigens visible even as cancers dismantle the presentation machinery.
In patients on long-term hemodialysis, beta-2 microglobulin accumulates because renal clearance is lost and because chronic inflammation favors its production. The protein then deposits as amyloid fibrils, predominantly in joints, bones, and synovial tissue, producing a painful and progressive condition known as dialysis-related amyloidosis. The deposited subunit is called Abeta2M, and structural studies show that aggregation begins from native-like monomers whose conformation fluctuates around specific regions, including a cis-configured proline and exposed loops. Amyloidogenic variants such as the D76N mutant populate intermediate states that are more accessible and more hydrophobic, accelerating fibril formation. Metal ions, especially copper, and the collagen-rich environment of connective tissue further promote assembly. Because the native protein is already compact, the transition to fibrils depends on subtle local unfolding rather than global denaturation. Understanding these early conformational events guides strategies that stabilize the folded state or block the interfaces that link monomers into the cross-beta spine of the fibril.
References
| Target | Cat. No. | Product Name | Species | Application | Detection Sample | |
| B2M | DEIA129J | β2-MG ELISA Kit | Human | Quantitative | Serum | Inquiry |
| DEIA1830 | Beta-2-Microglobulin ELISA Kit | Human | Quantitative | Urine, serum, plasma | Inquiry | |
| DEIA-BJ2510 | Mouse β2 Microglobulin ELISA Kit | Mouse | Quantitative | Serum, plasma, tissue homogenates and other biological fluids. | Inquiry |
| Target | Cat. No. | Product Name | Expression System | Tag/Conjugate | Application | |
| B2M | DAG108 | Human Urine β2-MICROGLOBULIN | N/A | Unconjugated | N/A | Inquiry |
| DAG-WT1847 | Recombinant Human beta-2-microglobulin protein | HEK293 cells | His | ELISA, CLIA, LFIA | Inquiry | |
| DAG-WT2605 | Beta-2 microglobulin (B2M) control | N/A | Unconjugated | Calibration, Control | Inquiry | |
| DAG-WT3252 | Recombinant Human B2-MG | CHO cells | His | ELISA | Inquiry | |
| DAGA-742 | Recombinant beta-2-microglobulin protein [His] | E. coli | His | N/A | Inquiry | |
| DAGA-741 | Recombinant beta-2-microglobulin antigen (aa 22-119) | E. coli | TBD | Controls, Calibrators, ELISA, Blotting | Inquiry | |
| DAG-WT2159 | Recombinant Human beta 2-Microglobulin [His] | HEK293 cells | His | Immunoassays | Inquiry |
Loading ......
